Business Wire

Premier Farnell’s New CAD Tool Interface, DesignLink, Enables Electronic Design Engineers to Find and Specify Millions of Parts Directly from within the Design Environment

Share
PREMIER-FARNELL-PLC

CAD Tool Vendors Invited to Partner with Global Electronics Distributor to Provide This Benefit

Premier Farnell’s New CAD Tool Interface, DesignLink, Enables
Electronic Design Engineers to Find and Specify Millions of
Parts Directly from within the Design Environment

Premier Farnell plc (LSE:pfl), the leading multi-channel, high service distributor supporting millions of engineers and purchasing professionals worldwide, has introduced DesignLink, a new web service environment that provides an electronic interface to major CAD (Computer Aid Design) tools. This will allow electronic designer engineers to immediately search and find parts from within their CAD design environment without ever having to leave it.

Developed in close collaboration with EMA, the developer of Component Information Portal (CIP), a bridge software to Cadence’s OrCAD CAD tool, the new Coupling Interface allows the designer to take the manufacturer’s data and use it directly in their schematic design instead of the having to research them via the web; they can also be sure that they are using active parts and then simply import part attributes into the design or local parts database. The coupling interfaces directly with the Premier Farnell companies’ websites in 40 different countries giving access to over 4,000,000 items from 3,500 leading manufacturers, all with data and pricing in local language and currencies, and further underpins the distribution group’s commitment to understanding the needs of its design engineering customers and delivering leading edge solutions. The Group’s strategic direction has seen it focussed on providing products, information, software and services to meet the needs of electronic design engineers globally and DesignLink represents another major advance.

Randall Restle, Director of Global Technical Marketing, said: "This new capability maps out the future of integration in the design cycle. Our customers are the same as those of the CAD vendors and DesignLink will allow us to support them better in the early stages of the design cycle. It seamlessly links everything together; allowing a designer to see what parts can fit his design by part or keyword search. He can then check availability for next day delivery without ever having to leave his design environment – it integrates our product database right into the design environment. We invite CAD tool developers to get in touch so we can help them to integrate our extensive product database into their CAD tools. Our beta testing has indicated that designers love this product and it will become a key "must have" during CAD tool choice."

Premier Farnell invites all manufacturers of CAD tools to contact them directly to discuss implementing the DesignLink interface with their design environment. The Group will be rapidly increasing their global capability to interface with a wide range of CAD platforms this year as they expand their support to meet the unique needs of their electronic design engineering customers.

Whether CAD tool manufacturer or electronic design engineer, to learn more about this exciting new development, e-mail DesignLink@premierfarnell.com .

element14 , a new technical portal and community for design engineers, provides a unique platform from which to launch new design tools and reach millions of electronic design engineers world-wide. A range of CAD Tools for electronic design engineers will also soon be available on element14. To follow or comment on this latest innovation visit www.element-14.com .

About Premier Farnell

Premier Farnell plc (LSE:pfl) is a leading high service, multi-channel distributor of electronic, and industrial products and specialist services throughout Europe, the Americas and Asia Pacific. It goes to market with a differentiated value proposition, world-class marketing, a stocked range of 450,000+ products, and access to 4,000,000 more items from 3,500 top manufacturers. The company has group sales of £823.1m and over 4,100 employees globally.

While global in scope, Premier Farnell recognizes the individual needs of each market and has continued to internationalize its model accordingly, trading locally under different brand names. Its primary electronics businesses trade as Farnell in the UK, India, Europe, Australia and New Zealand, Newark in the US, Canada and Mexico, and Premier Electronics in China and Hong Kong. In Singapore, Malaysia, and Brazil the operation is known as Farnell Newark.

For more information visit the website at www.PremierFarnell.com .

- End -

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact:

Jenny Peters
Head of Corporate Communication
Premier Farnell plc, and Asia
Tel: +44 (0) 207 851 4102
Email: jpeters@premierfarnell.com
Web: www.premierfarnell.com
or
Jonathan Roberts
Account Director
Pinnacle Marketing Communications Ltd,
Tel: +44 (0) 208 429 6540
Email: jonathan@pinnaclemarcom.com
Web: www.pinnaclemarcom.com
or
Janice Fleisher
PR & Communications Manager
Newark
The Americas
Tel: +001 (1) 773 907 5941
Email: jfleisher@newark.com
Web: www.newark.com
or
Philip Crampton
Marketing Manager
Farnell
Europe
Tel: +44 (0) 113 279 0101 ext 3433
Email: pcrampton@premierfarnell.com
Web : www.farnell.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release

Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g

Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 04:00:00 CEST | Press release

Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance to Fit the Local Audience. Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 03:11:00 CEST | Press release

Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 114.5.2025 23:03:00 CEST | Press release

–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated–Oveporexton Found to be Generally Safe and Well Tolerated–Phase 3 Readout of Oveporexton Anticipated in 2025 Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo thro

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 22:05:00 CEST | Press release

Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignanciesFour oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation scie

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye